The Dana-Farber Cancer Institute has reportedly barred trustees from newly investing in biotechs created to license its science, leading to the resignation of board members including a co-founder of C4 Therapeutics.
Under the old policy, trustees could invest in startups based on Dana-Farber research and, before a rethink in 2017, could negotiate licensing deals with the cancer center on behalf of startups. The policy allowed Marc Cohen, who became a Dana-Farber trustee in 2004, to invest in startups and take part in negotiations between the cancer center and biotechs he helped set up, including C4.
